Nephrotoxins and acute kidney injury - The consensus of the Taiwan acute kidney injury Task Force

J Formos Med Assoc. 2022 May;121(5):886-895. doi: 10.1016/j.jfma.2021.12.007. Epub 2022 Jan 5.

Abstract

The Taiwan Acute Kidney Injury (AKI) Task Force conducted a review of data and developed a consensus regarding nephrotoxins and AKI. This consensus covers: (1) contrast-associated AKI; (2) drug-induced nephrotoxicity; (3) prevention of drug-associated AKI; (4) follow up after AKI; (5) re-initiation of medication after AKI. Strategies for the avoidance of contrast media related AKI, including peri-procedural hydration, sodium bicarbonate solutions, oral N-acetylcysteine, and iso-osmolar/low-osmolar non-ionic iodinated contrast media have been recommended, given the respective evidence levels. Regarding anticoagulants, both warfarin and new oral anticoagulants have potential nephrotoxicity, and dosage should be reduced if renal pathology exam proves renal injury. Recommended strategies to prevent drug related AKI have included assessment of 5R/(6R) reactions - risk, recognition, response, renal support, rehabilitation and (research), use of AKI alert system and computerized decision support. In terms of antibiotics-associated AKI, avoiding concomitant administration of vancomycin and piperacillin-tazobactam, monitoring vancomycin trough level, switching from vancomycin to teicoplanin in high-risk patients, and replacing conventional amphotericin B with lipid-based amphotericin B have been shown to reduce drug related AKI. With respect to non-steroidal anti-inflammatory drug associated AKI, it is recommended to use these drugs cautiously in the elderly and in patients receiving renin-angiotensin-aldosterone system inhibitors/diuretics triple combinations.

Keywords: Acute kidney injuries; Contrast; Nephrotoxicity.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Acute Kidney Injury* / drug therapy
  • Acute Kidney Injury* / prevention & control
  • Aged
  • Amphotericin B / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Anticoagulants / therapeutic use
  • Consensus
  • Contrast Media / adverse effects
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Piperacillin / adverse effects
  • Retrospective Studies
  • Taiwan
  • Vancomycin*

Substances

  • Anti-Bacterial Agents
  • Anticoagulants
  • Contrast Media
  • Vancomycin
  • Amphotericin B
  • Piperacillin